Advances and challenges in the development and production of effective plant-based influenza vaccines

Expert Review of Vaccines

Volumn 14, Issue 4, 2015, Pages 519-535

  Yusibov, Vidadi ^a   Kushnir, Natasha ^a   Streatfield, Stephen J ^a  

^a Fraunhofer USA Inc   (United States)

Author keywords

clinical development; influenza; plant expression system; subunit vaccine; transient expression; virus like particle

Indexed keywords

INFLUENZA VACCINE; RECOMBINANT PROTEIN; SUBUNIT VACCINE; VIRUS LIKE PARTICLE VACCINE;

COST; DOWNSTREAM PROCESSING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENE TARGETING; HETEROLOGOUS EXPRESSION; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H1N1; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REVIEW; SEROCONVERSION; SWINE INFLUENZA; TRANSIENT EXPRESSION; VACCINE PRODUCTION; VIRUS VIRULENCE; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG SCREENING; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROCEDURES; TRANSGENIC PLANT; TRENDS;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; INFLUENZA VACCINES; PLANTS, GENETICALLY MODIFIED; VACCINES, SUBUNIT; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84924360089     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.989988     Document Type: Review

References (181)

1. Lamb RA, Krug RM. Orthomyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, Griffin DE, Editors Fields Virology. 4th Edition. Lippincott, Williams & Wilkins; Philadelphia, USA; 2001. p. 1487-531
2. Ruigrok RWH. Structure of influenza A, B and C viruses. In: Nicholson KG, Webster RG, Hay AJ, Editors Textbook of Influenza. Blackwell Science; Oxford, UK; 1998. p. 29-42
3. Centers for Disease Control and Prevention (CDC). Estimates of deaths associated with seasonal influenza-United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010;59:1057-62
4. World Health Organization. Influenza (Seasonal). Media Centre. Fact sheet o211. 2009. Available from: www.who.int/mediacentre/factsheets/fs211/en/index.html [Last accessed on 30 May 2014]
5. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009;325:197-201
6. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;360: 2605-15
7. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009;361:1945-52
8. World Health Organization. D-G statement. 2009. Available from: www.who. int/mediacentre/news/statements/2009/h1n1pandemicphase620090611/en/index.html [Last accessed on 30 May 2014]
9. Centers for Disease Control and Prevention. Information on Avian Influenza. Available from: www.cdc.gov/flu/avianflu/index.htm [Last accessed on 30 May 2014]
10. World Health Organization. Avian Influenza in Humans. Available from: www.who.int/influenza/human-animal-interface/avian-influenza/en/ [Last accessed on 30 May 2014]
11. World Health Organization. Cumulative Number of Confirmed Human Cases for Avian Influenza; A (H5N1) reported to WHO, 2003-2012. Available from: www.who.int/influenza/human-animal-interface/EN-GIP-20120607CumulativeNumberH5N1cases.pdf [Last accessed on 30 May 2014]
12. Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009;361:2405-13
13. Liang XF, Wang HQ, Wang JZ, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010;375:56-66
14. Plennevaux E, Sheldon E, Blatter M, et al. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010;375: 41-8
15. Keitel WA, Campbell JD, Treanor JJ, et al. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis 2008;198:1309-16
16. Nolan TM, Richmond PC, Skeljo MV, et al. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 2008;26:4160.4167
17. Matthews JT. Egg-based production of influenza vaccine: 30 years of commercial experience. The Bridge (Nat Acad Eng) 2006;36(3):17-24
18. Schultz-Cherry S, Jones JC. Influenza vaccines: the good, the bad, and the eggs. Adv Virus Res 2010;77:63-84
19. Michiels B, Govaerts F, Remmen R, et al. A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine 2011;29(49):9159-70
20. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012;12(1): 36-44
21. Skowronski DM, Janjua NZ, De Serres G, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One 2014;9(3):e92153
22. Murray K. Application of recombinant DNA techniques in the development of viral vaccines. Vaccine 1988;6(2):164-74
23. Pielak RM, Chou JJ. Influenza M2 proton channels. Biochim Biophys Acta 2011; 1808(2):522-9
24. Noda T, Sagara H, Yen A, et al. Architecture of ribonucleoprotein complexes in influenza A virus particles. Nature 2006;439:490-2
25. Gómez-Puertas P, Albo C, Pérez-Pastrana E, et al. Influenza virus matrix protein is the major driving force in virus budding. J Virol 2000;74(24):11538-47
26. Steinhauer DA, Wharton SA. Structure and function of the haemagglutinin. In: Nicholson KG, Webster RG, Hay AJ, Editors Textbook of Influenza. Blackwell Science; Oxford, UK; 1998. p. 54-64
27. Colman PM. Structure and function of the neuraminidase. In: Nicholson KG, Webster RG, Hay AJ, Editors Textbook of Influenza. Blackwell Science; Oxford, UK; 1998. p. 65-73
28. Varghese JN, Laver WG, Colman PM. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution. Nature 1983;303:35-40
29. Palese P, Compans RW. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-Ntrifluoroacetylneuraminic acid (FANA): mechanism of action. J Gen Virol 1976;33: 159-63
30. Wilson IA, Skehel JJ, Wiley DC. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution. Nature 1981;289:366-73
31. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000;69:531-69
32. McCown MF, Pekosz A. The influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging. J Virol 2005;79(6): 3595-605
33. McCown MF, Pekosz A. Distinct domains of the influenza a virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production. J Virol 2006;80(16):8178-89
34. Chen BJ, Leser GP, Jackson D, Lamb RA. The influenza virus M2 protein cytoplasmic tail interacts with the M1 protein and influences virus assembly at the site of virus budding. J Virol 2008;82(20):10059-70
35. Han T, Marasco WA. Structural basis of influenza virus neutralization. Ann N Y Acad Sci 2011;1217:178-90
36. United States Food and Drug Administration. Guidance for Industry: clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines. May 2007. Available from: www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091985.pdf [Last accessed on 30 May 2014]
37. Wilkinson TM, Li CK, Chui CS, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012;18(2):274-80
38. Galli G, Medini D, Borgogni E, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA 2009; 106(10):3877-82
39. Pedersen GK, Madhun AS, Breakwell L, et al. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis 2012;206(2):158-66
40. McElhaney JE, Xie D, Hager WD, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006; 176(10):6333-9
41. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983;309(1):13-17
42. McElhaney JE, Ewen C, Zhou X, et al. Granzyme B: Correlates with protection and enhanced CTL. Vaccine 2009;27(18): 2418-25
43. Cox RJ. Correlates of protection to influenza virus, where do we go from here? Hum. Vaccin. Immunother 2013;9(2): 405-8
44. Celik E, Cali{dotless}k P. Production of recombinant proteins by yeast cells. Biotechnol Adv 2012;30(5):1108-18
45. Chen R. Bacterial expression systems for recombinant protein production: E. coli and beyond. Biotechnol Adv 2012;30(5):1102-7
46. Drugmand JC, Schneider YJ, Agathos SN. Insect cells as factories for biomanufacturing. Biotechnol Adv 2012; 30(5):1140-57
47. Zhu J. Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv 2012;30(5):1158-70
48. Jacobs PP, Callewaert N. N-glycosylation engineering of biopharmaceutical expression systems. Curr Mol Med 2009;9(7):774-800
49. Ellis RW, Gerety RJ. Key issues in the selection of an expression system for vaccine antigens. J Med Virol 1990;31(1):54-8
50. Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 2012;31(1):58-83.
51. Nardin EH, Oliveira GA, Calvo-Calle JM, et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect Immun 2004;72(11):6519-27
52. Tissot AC, Renhofa R, Schmitz N, et al. Versatile virus-like particle carrier for epitope based vaccines. PLoS One 2010; 5(3):e9809
53. Cox MM. Progress on baculovirus-derived influenza vaccines. Curr Opin Mol Ther 2008;10(1):56-61
54. Athmaram TN, Saraswat S, Santhosh SR, et al. Yeast expressed recombinant Hemagglutinin protein of novel H1N1 elicits neutralising antibodies in rabbits and mice. Virol J 2011;8:524
55. Murugan S, Ponsekaran S, Kannivel L, et al. Recombinant haemagglutinin protein of highly pathogenic avian influenza A (H5N1) virus expressed in Pichia pastoris elicits a neutralizing antibody response in mice. J. Virol. Meth 2013;187(1):20-5
56. Wu CY, Yeh YC, Yang YC, et al. Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS One 2010;5(3):e9784
57. Mischler R, Metcalfe IC. Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine 2002;20(Suppl 5): B17-23
58. Amorij JP, Huckriede A, Wilschut J, et al. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm Res 2008;25(6):1256-73
59. Markham AP, Barrett BS, Esfandiary R, et al. Formulation and immunogenicity of a potential multivalent type III secretion system-based protein vaccine. J Pharm Sci 2010;99(11):4497-509
60. Choudhari SP, Pendleton KP, Ramsey JD, et al. A systematic approach toward stabilization of CagL, a protein antigen from Helicobacter pylori that is a candidate subunit vaccine. J Pharm Sci 2013;102(8): 2508-19
61. Tiwari S, Verma PC, Singh PK, Tuli R. Plants as bioreactors for the production of vaccine antigens. Biotechnol Adv 2009; 27(4):449-67
62. Rybicki EP. Plant-made vaccines for humans and animals. Plant Biotechnol J 2010;8(5):620-37
63. Mett V, Farrance CE, Green BJ, Yusibov V. Plants as biofactories. Biologicals 2008; 36(6):354-8
64. Sharma AK, Sharma MK. Plants as bioreactors: recent developments and emerging opportunities. Biotechnol Adv 2009;27(6):811-32
65. Matzke MA, Mette MF, Matzke AJ. Transgene silencing by the host genome defense: implications for the evolution of epigenetic control mechanisms in plants and vertebrates. Plant Mol Biol 2000;43(2-3): 401-15
66. Verma D, Daniell H. Chloroplast vector systems for biotechnology applications. Plant Physiol 2007;145(4):1129-43
67. Daniell H, Singh ND, Mason H, Streatfield SJ. Plant-made vaccine antigens and biopharmaceuticals. Trends Plant Sci 2009;14(12):669-79
68. Streatfield SJ. Approaches to achieve high-level heterologous protein production in plants. Plant Biotechnol J 2007;5(1):2-15
69. Yusibov V, Streatfield SJ, Kushnir N, et al. Hybrid viral vectors for vaccine and antibody production in plants. Curr Pharm Des 2013;19(31):5574-86
70. Lico C, Santi L, Twyman RM, et al. The use of plants for the production of therapeutic human peptides. Plant Cell Rep 2012;31(3):439-51
71. Yusibov V, Streatfield SJ, Kushnir N. Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond. Hum Vaccin 2011;7:313-21
72. Shaaltiel Y, Bartfeld D, Hashmueli S, et al. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol J 2007;5:579-90
73. Mullard A. 2012;FDA drug approvals. Nat Rev Drug Discov 2013;12(2):87-90
74. McCormick AA, Kumagai MH, Hanley K, et al. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proc Natl Acad Sci USA 1999;96(2):703-8
75. McCormick AA, Reddy S, Reinl SJ, et al. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study. Proc Natl Acad Sci USA 2008;105(29):10131-6
76. D'Aoust MA, Lavoie PO, Couture MM, et al. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J 2008;6(9):930-40
77. D'Aoust MA, Couture MM, Charland N, et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J 2010;8:607-19
78. Gleba Y, Klimyuk V, Marillonnet S. Magnifection-a new platform for expressing recombinant vaccines in plants. Vaccine 2005;23(17-18):2042-8
79. Bendandi M, Marillonnet S, Kandzia R, et al. Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma. Ann Oncol 2010;21:2420-7
80. Vezina L-P, D'Aoust MA, Landry N, et al. Plants as an Innovative and Accelerated Vaccine-Manufacturing Solution. BioPharm Inter Suppl 2011;25(5):s27-30
81. Sainsbury F, Lomonossoff GP. Extremely high-level and rapid transient protein production in plants without the use of viral replication. Plant Physiol 2008;148(3): 1212-18
82. Musiychuk K, Stephenson N, Bi H, et al. A launch vector for the production of vaccine antigens in plants. Influenza Other Respir Viruses 2007;1:19-25
83. Chichester JA, Musiychuk K, de la Rosa P, et al. Immunogenicity of a subunit vaccine against Bacillus anthracis. Vaccine 2007; 25(16):3111-14
84. Chichester JA, Musiychuk K, Farrance CE, et al. A single component two-valent LcrVF1 vaccine protects non-human primates against pneumonic plague. Vaccine 2009; 27(25-26):3471-4
85. Mett V, Lyons J, Musiychuk K, et al. A plant-produced plague vaccine candidate confers protection to monkeys. Vaccine 2007;25:3014-17
86. Mett V, Musiychuk K, Bi H, et al. A plant-produced influenza subunit vaccine protects ferrets against virus challenge. Influenza Other Respir Viruses 2008;2(1): 33-40
87. Shoji Y, Chichester JA, Bi H, et al. Plant-expressed HA as a seasonal influenza vaccine candidate. Vaccine 2008;26:2930-4
88. Shoji Y, Bi H, Musiychuk K, et al. Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza. Vaccine 2009a;27:1087-92
89. Shoji Y, Farrance CE, Bi H, et al. Immunogenicity of hemagglutinin from A/Bar-headed Goose/Qinghai/1A/05 and A/Anhui/1/05 strains of H5N1 influenza viruses produced in Nicotiana benthamiana plants. Vaccine 2009b;27(25-26):3467-70
90. Shoji Y, Chichester JA, Jones M, et al. Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1and H5N1 influenza. Hum Vaccin 2011a;7(Suppl):41-5
91. Jones RM, Chichester JA, Mett V, et al. A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice. PLoS One 2013;8(11):e79538
92. World Health Organization. Guidelines for national authorities on quality assurance for biological products. Annex 2. WHO Technical Report Series, No. 822. 1992
93. Van der Laan JW, Minor P, Mahoney R, et al. WHO Informal Consultation Group. WHO informal consultation on scientific basis for regulatory evaluation of candidate human vaccines from plants, Geneva, Switzerland 24-25 January 2005. Vaccine 2006;24:4271-8
94. United States Food and Drug Administration. Guidance for Industry: drugs, biologics and medical devices derived from bioengineered plants for use in humans and animals. Draft Guidance. September 2002. Available from: www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/ucm124811.pdf [Last accessed on 30 May 2014]
95. European Agency for the Evaluation of Medicinal Products. Guideline on the quality of biological active substances produced by stable transgene expression in higher plants. Draft 2. July 2006. Available from: www.triskel.com/4%20Guideline% 20higher%20plants.pdf [Last accessed on 30 May 2014]
96. Fischer R, Schillberg S, Hellwig S, et al. GMP issues for recombinant plant-derived pharmaceutical proteins. Biotechnol Adv 2012;30(2):434-9
97. Fischer R, Schillberg S, Buyel JF, Twyman RM. Commercial aspects of pharmaceutical protein production in plants. Curr Pharm Des 2013;19(31):5471-7
98. Sigma-Aldrich. Available from: www.sigmaaldrich.com/safc/products/contractmanufacturing-solutions/therapeuticproteins/native-sourced-extraction-andpurification.html) [Last accessed on 30 May 2014]
99. Kentucky BioProcessing. Available from: www.kbpllc.com [Last accessed on 30 May 2014]
100. Lai H, Chen Q. Bioprocessing of plant-derived virus-like particles of Norwalk virus capsid protein under current Good Manufacture Practice regulations. Plant Cell Rep 2012;31(3):573-84
101. Bayer HealthCare. Available from: http://press.healthcare.bayer.com/en/press/newsdetails-page.php/13588) [Last accessed on 30 May 2014]
102. Klimyuk V, Pogue G, Herz S, et al. Production of recombinant antigens and antibodies in Nicotiana benthamiana using 'magnifection' technology: GMP-compliant facilities for small- and large-scale manufacturing. Curr Top Microbiol Immunol 2014;375:127-54
103. Wirz H, Sauer-Budge AF, Briggs J, et al. Automated production of plant-based vaccines and pharmaceuticals. J Lab Autom 2012;17(6):449-57
104. Fraunhofer USA Center for Molecular Biotechnology. Available from: http://fhcmb.org/ [Last accessed on 30 May 2014]
105. Chichester JA, Jones RM, Green BJ, et al. Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in healthy adults. Viruses 2012;4(11):3227-44
106. Cummings JF, Guerrero ML, Moon JE, et al. Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1) pdm09 virus: a Phase 1 dose-escalation study in healthy adults. Vaccine 2014; 32(19):2251-9.
107. Pharmaceutical-technology. Fraunhofer Plant-Based Vaccine Factory, United States of America. Available from: www.pharmaceutical-technology.com/projects/fraunhofernewplantba/ Last accessed on 30 May 2014]
108. Fraunhofer. Automated plant factory for the production of vaccines. Research News - Special Issue Jun 10, 2013. Available from: www.fraunhofer.de/en/press/research-news/2013/june/automated-plant-factory-for-theprodution-of-vaccines.html [Last accessed on 30 May 2014]
109. Icon Genetics. Company Profile. Available from: www.icongenetics.com/html/03.htm [Last accessed on 30 May 2014]
110. Icon Genetics. Pilot plant for future-oriented technology opens in Halle. June 16, 2008. Available from: www.icongenetics.com/html/5948.htm [Last accessed on 30 May 2014]
111. Icon Genetics. Icon Genetics successfully completes Phase I clinical study with personalized vaccines for treatment of non-Hodgkin's lymphoma. Munich, January 31, 2014. Available from: www.icongenetics.com/html/5975.htm) [Last accessed on 30 May 2014]
112. Rybicki EP. Third International Conference on Plant-Based Vaccines and Antibodies. Expert Rev Vaccines 2009;8:1151-5
113. Fraunhofer Institute for Molecular Biology and Applied Ecology. Pharma-Planta: production of Clinical-grade API in Tobacco. Available from: www.ime. fraunhofer.de/en/businessareasMB/integrated-production-platforms/pharmaplanta-productionofclinicalgradeapiintobacco.html [Last accessed on 30 May 2014]
114. Pharmaceutical Processing. Caliber Recognized for Excellence In Technology. Available from: www.pharmpro.com/articles/2014/03/caliber-recognizedexcellence-technology [Last accessed on 30 May 2014]
115. Shepard S. Spotlight. Letter to the Editor. BioProcess Intern 2011;9(6):8-9
116. The Business Journals. Medicago Successfully Completes the Production of More Than Ten Million Doses of H1N1 VLP Influenza Vaccine in One Month. Medicago Inc. Press Release. July 24 2012. Available from: www.bizjournals.com/prnewswire/press-releases/2012/07/T0809 [Last accessed on 30 May 2014]
117. The Business Journals. Medicago reports positive U.S. clinical trial results for its H1N1/seasonal influenza vaccine. Medicago Inc. Press Release. June 8, 2011. Available from: www.bizjournals.com/prnewswire/press-releases/2011/06/08/TO211 [Last accessed on 30 May 2014].
118. Landry N, Ward BJ, Trépanier S, et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 2010; 5(12):e15559.
119. McKenna M. The Pandemic Vaccine Puzzle. A seven-part series on the chances for immunizing the world against pandemic flu. Minneapolis, MN: CIDRAP News, November 15. 2007. Available from: www.cidrap.umn.edu/news-perspective/2007/11/pandemic-vaccine-puzzle-seven-part-serieschances-immunizing-world-against#-Part-2:-Vaccine [Last accessed on 30 May 2014]
120. Shoji Y, Farrance CE, Bautista J, et al. A plant-based system for rapid production of influenza vaccine antigens. Influenza Other Respir Viruses 2012;6(3):204-10
121. Zhang S, Sherwood RW, Yang Y, et al. Comparative characterization of the glycosylation profiles of an influenza hemagglutinin produced in plant and insect hosts. Proteomics 2012;12(8):1269-88
122. Study of the Safety and Immunogenicity of H1N1 Vaccine. Available from: http://clinicaltrials.gov/show/NCT01177202
123. Wu J, Li W, Wang HQ, et al. A rapid immune response to 2009 influenza A (H1N1) vaccines in adults: a randomized, double-blind, controlled trial. J Infect Dis 2010;202(5):675-80
124. Zhu FC, Wang H, Fang HH, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009;361(25): 2414-23
125. Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults. Available from: http://clinicaltrials.gov/show/NCT01250795
126. Wei CJ, Xu L, Kong WP, et al. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J Virol 2008;82(13): 6200-8
127. Wilson IA, Cox NJ. Structural basis of immune recognition of influenza virus hemagglutinin. Annu Rev Immunol 1990;8: 737-71
128. Vanlandschoot P, Beirnaert E, Neirynck S, et al. Molecular and immunological characterization of soluble aggregated A/Victoria/3/75 (H3N2) influenza haemagglutinin expressed in insect cells. Arch Virol 1996;141:1715-26
129. Kammerer RA, Kostrewa D, Progias P, et al. A conserved trimerization motif controls the topology of short coiled coils. Proc Natl Acad Sci USA 2005;102:13891-6
130. Shoji Y, Jones RM, Mett V, et al. A plant-produced H1N1 trimeric hemagglutinin protects mice from a lethal influenza virus challenge. Hum Vaccin Immunother 2013;9(3):pii: 23234
131. Deml L, Speth C, Dierich MP, et al. Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol 2005;42(2):259-77
132. Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods 2006;40(1):60-5
133. Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines 2007;6(3):381-90
134. Song JM, Hossain J, Yoo DG, et al. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology 2010;405(1):165-75
135. Quan FS, Huang C, Compans RW, Kang SM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 2007;81(7):3514-24
136. McBurney SP, Young KR, Ross TM. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology 2007;358(2):334-46
137. Kang SM, Yoo DG, Lipatov AS, et al. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One 2009;4(3):e4667
138. Kang SM, Kim MC, Compans RW. Virus-like particles as universal influenza vaccines. Expert Rev Vaccines 2012;11(8): 995-1007
139. Paliard X, Liu Y, Wagner R, et al. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res Hum. Retroviruses 2000;16(3):273-82
140. Schirmbeck R, Böhm W, Reimann J. Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen. Intervirology 1996;39(1-2):111-19
141. Win SJ, Ward VK, Dunbar PR, et al. Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway. Immunol Cell Biol 2011;89(6): 681-8
142. Bachmann MF, Zinkernagel RM, Oxenius A. Immune responses in the absence of costimulation: viruses know the trick. J Immunol 1998;161(11):5791-4
143. Storni T, Lechner F, Erdmann I, et al. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J Immunol 2002; 168(6):2880-6
144. Storni T, Ruedl C, Schwarz K, et al. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 2004; 172(3):1777-85
145. Wang BZ, Quan FS, Kang SM, et al. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol 2008;82(23):11813-23
146. Wang BZ, Xu R, Quan FS, et al. Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS One 2010;5(11):e13972
147. Fiers W, De Filette M, El Bakkouri K, et al. M2e-based universal influenza A vaccine. Vaccine 2009;27(45):6280-3
148. GlaxoSmithKline. ENGERIX-B (Hepatitis B surface antigen [rys]). Prescribing Information. 2014
149. Merck & Co., Inc. Recombivax HB Hepatitis B Vaccine (Recombinant). Prescribing Information. 2014
150. Merck & Co., Inc. GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] Prescribing Information. 2014
151. GlaxoSmithKline. CERVARIX [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant]. Prescribing Information. 2014
152. Khurana S, Wu J, Verma N, et al. H5N1virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol 2011;85:10945-54
153. López-Macías C, Ferat-Osorio E, Tenorio-Calvo A, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 2011;29(44):7826-34.
154. Bright RA, Carter DM, Daniluk S, et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007;25(19):3871-8
155. Bright RA, Carter DM, Crevar CJ, et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 2008;3(1):e1501
156. Mahmood K, Bright RA, Mytle N, et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 2008;26(42):5393-9
157. Mumford RA, Barker I, Wood KR. The biology of the tospoviruses Ann. Appl. Biol 1996;128(1):159-83
158. Taliansky M, Torrance L, Kalinina NO. Role of plant virus movement proteins. Methods Mol Biol 2008;451:33-54
159. Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults. Available from: www.clinicaltrials.gov/ct2/show/NCT00984945?term=medicago&rank=1 [Last accessed on 30 May 2014]
160. Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in Adults. Available from: www.clinicaltrials.gov/ct2/show/NCT01302990? term=medicago&rank=5 [Last accessed on 30 May 2014]
161. Immunogenicity, Safety, Tolerability of a Plant-Made H5 VLP Influenza Vaccine. Available from: www.clinicaltrials.gov/ct2/show/NCT01244867?term=medicago&rank=3 [Last accessed on 30 May 2014]
162. Ward BJ, Landry N, Trépanier S, et al. Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines. Vaccine 2014; 32(46):6098-106
163. The Business Journals. Medicago reports positive Phase II final results for its avian flu pandemic vaccine. Medicago Inc. Press Release. June 30, 2011. Available from: www.bizjournals.com/prnewswire/press-releases/2011/06/30/TO669 [Last accessed on 30 May 2014]
164. H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers. Available from: http://clinicaltrials.gov/ct2/show/NCT01657929 [Last accessed on 30 May 2014]
165. Infectious Disease Research Institute. IDRI and Medicago Report Positive Results for Phase I Clinical Trial for an H5N1 Vaccine. Press Release. April 17, 2013. Available from: www.idri.org/press- 04-17-13.php [Last accessed on 30 May 2014]
166. Landry N, Pillet S, Favre D, et al. Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens. Clin Immunol 2014;154(2):164-77
167. Lico C, Mancini C, Italiani P, et al. Plant-produced potato virus X chimeric particles displaying an influenza virus-derived peptide activate specific CD8+ T cells in mice. Vaccine 2009;27(37): 5069-76
168. Meshcheriakova IuA, El'darov MA, Migunov AI, et al. Cowpea mosaic virus chimeric particles bearing ectodomain of matrix protein 2 (M2E) of influenza A virus: production and characteristics. Mol Biol (Mosk) 2009;43(4):741-50
169. MatićS, Rinaldi R, Masenga V, Noris E. Efficient production of chimeric human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants. BMC Biotechnol 2011;11:106
170. Gilbert N. Europe prepares for drugs from GM plants. Nature 2009;460:791
171. GlaxoSmithKline. FLUARIX (Influenza Virus Vaccine). Prescribing Information, 2013
172. Sanofi Pasteur. Fluzone (Influenza Virus Vaccine). Prescribing Information, 2013
173. United States Food and Drug Administration (FDA). FDA approves new seasonal influenza vaccine made using novel technology. News Release. January 16, 2013. Available from: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm335891.htm [Last accessed on 02 June 2014].
174. Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine. Available from: www.clinicaltrials.gov/ct2/show/NCT01991561? term=medicago&rank=2 [Last accessed on 30 May 2014]
175. Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults. Available from: www.clinicaltrials.gov/ct2/show/NCT01991587?term=medicago&rank=4 [Last accessed on 30 May 2014]
176. Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults. Available from: http://clinicaltrials.gov/ct2/show/NCT02233816? term=medicago&rank=3 [Last accessed on 10 November 2014]
177. Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like Particles (VLP) Quadrivalent Influenza Vaccine in the Elderly Population. Available from: http://clinicaltrials.gov/ct2/show/NCT02236052?term=medicago&rank=5 [Last accessed on 10 November 2014]
178. Centers for Disease Control and Prevention. Avian Influenza A (H7N9) Virus. Available from: www.cdc.gov/flu/avianflu/h7n9-virus.htm [Last accessed on 10 November 2014]
179. PR Newswire. Medicago is First in the World to Report Positive Interim Results for its H7N9 Pre-Clinical Trial. Press Release. June 6. 2013. Available from: www.prnewswire.com/news-releases/medicago-is-first-in-the-world-to-reportpositive-interim-results-for-its-h7n9-preclinical-trial-210378341.html [Last accessed on 10 November 2014]
180. Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults. Available from: www.clinicaltrials.gov/ct2/show/NCT02022163?term=nct02022163&rank=1 [Last accessed on 30 May 2014]
181. Mortimer E, Maclean JM, Mbewana S, et al. Setting up a platform for plant-based influenza virus vaccine production in South Africa. BMC Biotechnol 2012;12:14